Nuvation Bio Discontinues NUV-1511 Due to Efficacy Issues

An announcement from Nuvation Bio ( (NUVB) ) is now available.

On November 26, 2025, Nuvation Bio announced the discontinuation of NUV-1511, a compound from its drug-drug conjugate program, due to inconsistent efficacy. The company plans to redirect resources to other pipeline molecules and next-generation DDC candidates, while continuing to advance its other programs, including the commercial launch of IBTROZI and the development of safusidenib.

The most recent analyst rating on (NUVB) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Nuvation Bio stock, see the NUVB Stock Forecast page.

Spark’s Take on NUVB Stock

According to Spark, TipRanks’ AI Analyst, NUVB is a Neutral.

Nuvation Bio’s stock is primarily challenged by weak financial performance, characterized by ongoing losses and negative cash flows, despite a strong equity foundation. While there is short-term momentum in the stock price, the lack of sustainable income and negative valuation metrics, such as a negative P/E ratio, weigh heavily on the overall score. The stock’s speculative nature and reliance on future growth prospects contribute to its moderate overall score.

To see Spark’s full report on NUVB stock, click here.

More about Nuvation Bio

Nuvation Bio is a global, commercial-stage oncology company focused on developing first- or best-in-class medicines for diseases with significant unmet needs. The company is known for its innovative approach in cancer treatment, including the development of IBTROZI, a next-generation ROS1 inhibitor, and safusidenib, a potent mIDH1 inhibitor for glioma treatment.

Average Trading Volume: 8,907,327

Technical Sentiment Signal: Buy

Current Market Cap: $2.71B

Find detailed analytics on NUVB stock on TipRanks’ Stock Analysis page.